Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial

BACKGROUND: Cabozantinib is an orally available inhibitor of tyrosine kinases including VEGFR2 and c-MET. We performed a post hoc analysis to find associations between select plasma biomarkers and treatment response in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) who r...

Descripción completa

Detalles Bibliográficos
Autores principales: Leibowitz-Amit, Raya, Pintilie, Melania, Khoja, Leila, Azad, Arun A., Berger, Raanan, Laird, A. Douglas, Aftab, Dana T., Chi, Kim N., Joshua, Anthony M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4712499/
https://www.ncbi.nlm.nih.gov/pubmed/26762579
http://dx.doi.org/10.1186/s12967-015-0747-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4712499/
https://www.ncbi.nlm.nih.gov/pubmed/26762579
http://dx.doi.org/10.1186/s12967-015-0747-y

Ejemplares similares